Physician profile
Jonas Mansson
NPI 1144429606
$8,980.28
in general payments reported to CMS, 2019-2025
17 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2021: $2,069 · 2022: $2,219 · 2023: $120 · 2024: $2,989 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128 · Travel and Lodging: $1,143 · Gift: $23.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.89 |
| Travel and Lodging | $1,142.76 |
| Gift | $23.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,798.31 | 2021-2024 | Da Vinci Surgical System |
| Stryker Corporation | $1,129.78 | 2019 | |
| Arthrex, INC. | $642.50 | 2021-2022 | |
| Davol INC. | $564.53 | 2024 | Phasix Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.31 | 2019-2022 | |
| Covidien LP | $152.17 | 2019 | |
| Abbvie INC. | $137.28 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $62.01 | 2025 | |
| Janssen Biotech, INC. | $56.11 | 2022-2025 | Simponi, Remicade, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $47.15 | 2025 | Imfinzi |
| Ironwood Pharmaceuticals, INC | $41.26 | 2021-2023 | Linzess |
| Kerecis Limited | $37.83 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $23.18 | 2023 | Prevena |
| Smith+Nephew, INC. | $22.67 | 2025 | Collagenase Santyl |
| Djo, LLC | $21.17 | 2025 | Cmf |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.45 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $14.57 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonas Mansson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.